Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 1.096
Filtrer
1.
Cell Mol Biol (Noisy-le-grand) ; 70(6): 122-128, 2024 Jun 05.
Article de Anglais | MEDLINE | ID: mdl-38836672

RÉSUMÉ

Hypospadias, an oft-occurring penis anomaly, ranks among neonatal's foremost birth defects. The SRD5A2 can affect male reproductive system development and is abnormally expressed in its epithelial cells. This study exploration aimed at understanding the role of SRD5A2 in the development of hypospadias from a molecular perspective. SRD5A2 levels in hypospadias primary cells were analyzed by Western blot, while targeted interaction with miR-1199-5p was ascertained by dual-luciferase gene reporter assay. In vitro biological experiments were used to confirm the biological function of SRD5A2 in hypospadias. SRD5A2 expression was significantly upregulated, and miR-1199-5p expression was significantly downregulated in hypospadias primary cells. Intervention of SRD5A2 expression can affect cell proliferation, migration, invasion, EMT, and the expression of cell cycle-related proteins. Additionally, we found that SRD5A2 is regulated by upstream miR-1199-5p and can enhance the effect of SRD5A2 on hypospadias cells. Conclusions Silencing SRD5A2 promotes cell proliferation, invasion, and migration blocks the cell cycle at the G1 phase, and simultaneously promotes EMT, cell cycle, and cell proliferation-related protein expression. The biological function of SRD5A2 in hypospadias cells is regulated by miR-1199-5p. SRD5A2 may be an effective therapeutic target for hypospadias.


Sujet(s)
3-Oxo-5-alpha-Steroid 4-Dehydrogenase , Mouvement cellulaire , Prolifération cellulaire , Transition épithélio-mésenchymateuse , Hypospadias , Protéines membranaires , microARN , Hypospadias/génétique , Hypospadias/anatomopathologie , Hypospadias/métabolisme , Mâle , Humains , Transition épithélio-mésenchymateuse/génétique , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/génétique , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , Prolifération cellulaire/génétique , Protéines membranaires/métabolisme , Protéines membranaires/génétique , microARN/génétique , microARN/métabolisme , Mouvement cellulaire/génétique
2.
Chem Biol Interact ; 394: 110987, 2024 May 01.
Article de Anglais | MEDLINE | ID: mdl-38574835

RÉSUMÉ

Per- and polyfluoroalkyl substances (PFAS) are widely used synthetic chemicals that persist in the environment and bioaccumulate in animals and humans. There is growing evidence that PFAS exposure adversely impacts neurodevelopment and neurological health. Steroid 5α-reductase 1 (SRD5A1) plays a key role in neurosteroidogenesis by catalyzing the conversion of testosterone or pregnenolone to neuroactive steroids, which influence neural development, cognition, mood, and behavior. This study investigated the inhibitory strength and binding interactions of 18 PFAS on human and rat SRD5A1 activity using enzyme assays, molecular docking, and structure-activity relationship analysis. Results revealed that C9-C14 PFAS carboxylic acid at 100 µM significantly inhibited human SRD5A1, with IC50 values ranged from 10.99 µM (C11) to 105.01 µM (C14), and only one PFAS sulfonic acid (C8S) significantly inhibited human SRD5A1 activity, with IC50 value of 8.15 µM. For rat SRD5A1, C9-C14 PFAS inhibited rat SRD5A1, showing the similar trend, depending on carbon number of the carbon chain. PFAS inhibit human and rat SRD5A1 in a carbon chain length-dependent manner, with optimal inhibition around C11. Kinetic studies indicated PFAS acted through mixed inhibition. Molecular docking revealed PFAS bind to the domain between NADPH and testosterone binding site of both SRD5A1 enzymes. Inhibitory potency correlated with physicochemical properties like carbon number of the carbon chain. These findings suggest PFAS may disrupt neurosteroid synthesis and provide insight into structure-based inhibition of SRD5A1.


Sujet(s)
3-Oxo-5-alpha-Steroid 4-Dehydrogenase , Simulation de docking moléculaire , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/composition chimique , Animaux , Humains , Rats , Relation structure-activité , Protéines membranaires/métabolisme , Fluorocarbones/composition chimique , Fluorocarbones/métabolisme , Fluorocarbones/pharmacologie , Liaison aux protéines , Carbone/composition chimique , Carbone/métabolisme , Sites de fixation
3.
J Pathol ; 263(3): 300-314, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38606616

RÉSUMÉ

Steroid 5α reductase 2 (SRD5A2) converts testosterone to dihydrotestosterone and is crucial for prostatic development. 5α reductase inhibitors (5ARI) reduce prostate size in benign prostate hyperplasia (BPH) and ameliorate lower urinary tract symptoms secondary to BPH. However, the mechanisms of 5ARI functioning are still not fully understood. Here, we used a Srd5a2-/- mouse model and employed single-cell RNA sequencing to explore the impact of SRD5A2 absence on prostate cellular heterogeneity. Significant alterations in luminal epithelial cell (LE) populations were observed, alongside an increased proportion and proliferative phenotype of estrogen receptor 1 (ESR1)+ LE2 cells, following an SRD5A2-independent ESR1 differentiation trajectory. LE2 cells exhibited enhanced estrogen response gene signatures, suggesting an alternative pathway for prostate growth when SRD5A2 is absent. Human prostate biopsy analysis revealed an inverse correlation between the expressions of SRD5A2 and LE2 markers (ESR1/PKCα), and an inverse correlation between SRD5A2 and the clinical efficiency of 5ARI. These findings provide insights into 5ARI resistance mechanisms and potential alternative therapies for BPH-related lower urinary tract symptoms. © 2024 The Pathological Society of Great Britain and Ireland.


Sujet(s)
3-Oxo-5-alpha-Steroid 4-Dehydrogenase , Cellules épithéliales , Récepteur alpha des oestrogènes , Protéines membranaires , Souris knockout , Prostate , Hyperplasie de la prostate , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/génétique , Mâle , Animaux , Récepteur alpha des oestrogènes/métabolisme , Récepteur alpha des oestrogènes/génétique , Prostate/anatomopathologie , Prostate/métabolisme , Humains , Hyperplasie de la prostate/anatomopathologie , Hyperplasie de la prostate/métabolisme , Hyperplasie de la prostate/génétique , Cellules épithéliales/métabolisme , Cellules épithéliales/anatomopathologie , Protéines membranaires/métabolisme , Protéines membranaires/génétique , Souris , Inhibiteurs de la 5-alpha réductase/pharmacologie , Prolifération cellulaire , Modèles animaux de maladie humaine , Différenciation cellulaire , Symptômes de l'appareil urinaire inférieur/anatomopathologie , Symptômes de l'appareil urinaire inférieur/métabolisme
4.
J Steroid Biochem Mol Biol ; 241: 106516, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38582131

RÉSUMÉ

Epitestosterone is a stereoisomer of the active androgen testosterone and its circulating concentrations are similar to those of testosterone in women and children. However, its biological function and pathways of metabolism remain unknown. The structural similarity to testosterone suggests a potential function in the modulation of androgen receptor signalling. It is well established that the conversion of testosterone to 5α-dihydrotestosterone enhances local androgen receptor signalling. In this study, we show that epitestosterone is metabolized to 5α-dihydroepitestosterone by both human steroid 5α-reductase isoforms, SRD5A1 and SRD5A2. Using two different variations of a reporter assay for transactivation of the human androgen receptor, we show that epitestosterone is a partial AR agonist and that the 5α-reduction of epitestosterone increases its androgenic activity. In line with this, we show that 5α-reduction of epitestosterone reduces its ability to antagonize 5α-dihydrotestosterone-induced androgen receptor transactivation. In conclusion, we provide evidence that steroid 5α-reductases regulate the modulatory effect of epitestosterone on androgen receptor signalling.


Sujet(s)
3-Oxo-5-alpha-Steroid 4-Dehydrogenase , Épitestostérone , Protéines membranaires , Récepteurs aux androgènes , Activation de la transcription , Humains , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/génétique , Récepteurs aux androgènes/métabolisme , Récepteurs aux androgènes/génétique , Activation de la transcription/effets des médicaments et des substances chimiques , Protéines membranaires/métabolisme , Protéines membranaires/génétique , Épitestostérone/métabolisme , 5alpha-Dihydrotestostérone/métabolisme , Androgènes/métabolisme , Oxydoréduction
5.
Chem Biol Interact ; 394: 110971, 2024 May 01.
Article de Anglais | MEDLINE | ID: mdl-38521455

RÉSUMÉ

Selective Androgen Receptor Modulators (SARMs), particularly (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic-acid-methyl-ester (YK11), are increasingly popular among athletes seeking enhanced performance. Serving as an Androgen Receptor (AR) agonist, YK11 stimulates muscle growth while inhibiting myostatin. Our study delved into the impact of YK11 on the rat hippocampus, analyzing potential alterations in neurochemical mechanisms and investigating its synergistic effects with exercise (EXE), based on the strong relationship between SARM users and regular exercise. Utilizing Physiologically Based Pharmacokinetic (PBPK) modeling, we demonstrated YK11 remarkable brain permeability, with molecular docking analysis revealing YK11 inhibitory effects on 5-alpha-reductase type II (5αR2), suggesting high cell bioavailability. Throughout a 5-week experiment, we divided the animals into the following groups: Control, YK11 (0.35 g/kg), EXE (swimming exercise), and EXE + YK11. Our findings showed that YK11 displayed a high binding affinity with AR in the hippocampus, influencing neurochemical function and modulating aversive memory consolidation, including the downregulation of the BDNF/TrkB/CREB signaling, irrespective of EXE combination. In the hippocampus, YK11 increased pro-inflammatory IL-1ß and IL-6 cytokines, while reducing anti-inflammatory IL-10 levels. However, the EXE + YK11 group counteracted IL-6 effects and elevated IL-10. Analysis of apoptotic proteins revealed heightened p38 MAPK activity in response to YK11-induced inflammation, initiating the apoptotic cascade involving Bax/Bcl-2/cleaved caspase-3. Notably, the EXE + YK11 group mitigated alterations in Bcl-2 and cleaved caspase-3 proteins. In conclusion, our findings suggest that YK11, at anabolic doses, significantly alters hippocampal neurochemistry, leading to impairments in memory consolidation. This underscore concerns about the misuse risks of SARMs among athletes and challenges common perceptions of their minimal side effects.


Sujet(s)
Hippocampe , Simulation de docking moléculaire , Récepteurs aux androgènes , Animaux , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Récepteurs aux androgènes/métabolisme , Mâle , Rats , Facteur neurotrophique dérivé du cerveau/métabolisme , Apoptose/effets des médicaments et des substances chimiques , Rat Sprague-Dawley , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , Conditionnement physique d'animal , Cholestenone 5 alpha-reductase/métabolisme , Récepteur trkB/métabolisme
6.
Sci Rep ; 13(1): 19553, 2023 11 09.
Article de Anglais | MEDLINE | ID: mdl-37945678

RÉSUMÉ

The cloning and characterization of the complete coding sequence of the Clarias magur SRD5A1 (CmSRD5A1) gene, which encodes an enzyme responsible for regulating steroid levels by converting testosterone into 5α-dihydrotestosterone (DHT), have been successfully achieved. DHT plays a vital role in enabling the complete expression of testosterone's actions in neuroendocrine tissues. The ORF of the full-length cDNA sequence of SRD5A1 was 795 bp, translating into 265 amino acids, with a total length of 836 bp including UTRs. Like other vertebrates, the signal peptide analysis revealed that SRD5A1 is a non-secretory protein, and hydropathy profiles indicated that it is hydrophobic in nature. The 3D structure of CmSRD5A1 sequence generated above was predicted using highly accurate AlphaFold 2 in Google Colab online platform. CmSRD5A1 contains seven transmembrane helices connected by six loops, with the N-termini located on the periplasmic side and C-termini on the cytosolic side. Structural superimposition with known bacterial and human SRD5As showed very high structural similarity. The electrostatic potential calculation and surface analysis of CmSRD5A1 revealed the presence of a large cavity with two openings one highly electropositive towards the cytosolic side and another relatively neutral towards the transmembrane region. The structural comparison revealed that the electropositive side of the cavity should bind to NADPH and the steroid hormone in the hydrophobic environment. Polar residues binding to NADPH are highly conserved and the same as known strictures. The conserved residues involved in hydrogen bonding with the ketone group at C-3 in the steroids hence fevering Δ4 double-bond reduction are identified as E66 and Y101. Our findings showed that SRD5A1 expression was lower during the spawning phase than the preparatory phase in female fish, while the administration of Ovatide (a GnRH analogue) resulted in up-regulation of expression after 6 h of injection in the ovary. In males, the lowest expression was observed during the preparatory phase and peaked at 16 h post- Ovatide injection in the testis. The expression of SRD5A1 in the brain of female fish was slightly higher during the Ovatide stimulation phase than the spawning phase. This study represents the first report on the cloning and characterization of the full-length cDNA of SRD5A1 in Indian catfish.


Sujet(s)
Poissons-chats , Cholestenone 5 alpha-reductase , Mâle , Animaux , Femelle , Humains , Cholestenone 5 alpha-reductase/métabolisme , Poissons-chats/génétique , Poissons-chats/métabolisme , ADN complémentaire/génétique , NADP/métabolisme , Séquence d'acides aminés , Testostérone/métabolisme , 5alpha-Dihydrotestostérone/métabolisme , Stéroïdes/métabolisme , Clonage moléculaire , Protéines membranaires/génétique , Protéines membranaires/métabolisme , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/génétique , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme
7.
Methods Enzymol ; 689: 263-276, 2023.
Article de Anglais | MEDLINE | ID: mdl-37802573

RÉSUMÉ

The two human steroid 5α-reductase (5αR) enzymes catalyze the conversion 3-keto-Δ4-steroids to their 5α-reduced congeners. In the genital skin and prostate, the type 2 isoenzyme converts testosterone (T) to the more potent androgen 5α-dihydrotestosterone (DHT), and intracellular DHT is essential for the morphogenesis of the undifferentiated external genitalia to the male phenotype. Both isoenzymes also metabolize other 19- and 21-carbon 3-keto-Δ4-steroids, both endogenous compounds and some steroid-based drugs. Rigorous biochemical studies have been limited due to the extremely hydrophobic nature of these proteins. We have described the heterologous expression of these enzymes in bacteria, their purification with affinity chromatography, and the reconstitution of activity in liposomes. This article details these procedures, as well as reconstitution in phospholipid nanodiscs and enzyme assay.


Sujet(s)
3-Oxo-5-alpha-Steroid 4-Dehydrogenase , Liposomes , Humains , Mâle , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/génétique , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , Phospholipides , Testostérone/métabolisme , 5alpha-Dihydrotestostérone/métabolisme
8.
Cancer Prev Res (Phila) ; 16(3): 139-151, 2023 03 01.
Article de Anglais | MEDLINE | ID: mdl-36517462

RÉSUMÉ

Cinnamon and its bioactive compounds inhibit prostate cancer cell proliferation in vitro. The aim of the current study was to assess the chemopreventive efficacy of cinnamon (CN) and its bioactive compounds in vivo using N-methyl-N-nitrosourea (MNU) and testosterone (T) to induce prostate carcinogenesis in male Wistar/National Institute of Nutrition rats. Cancer-induced (CI) rats (n = 10) developed prostatic hyperplasia and prostatic intraepithelial neoplasia. These histopathologic changes were diminished in CI rats fed for 4 months with diets supplemented with either CN (n = 20) or its bioactive compounds (cinnamaldehyde, n = 10 and procyanidin B2, n = 10). Androgen receptor (AR) expression was lower in the prostates of CI rats than in control, but the AR target gene, probasin, was robustly upregulated. Treatment of CI rats with CN or its bioactive compounds upregulated AR expression but inhibited the expression of the 5-alpha reductase genes (Srd5a1 and Srd5a2) and did not further increase probasin expression, suggesting blunted transcriptional activity of AR due to the limited availability of dihydrotestosterone. MNU+T induced an altered oxidant status in rat prostate, which was reflected by an increase in lipid peroxidation and DNA oxidation. These changes were completely or partially corrected by treatment with CN or the bioactive compounds. CN and its active components increased the activity of the apoptotic enzymes caspase-8 and caspase-3 in the prostates of CI rats. In conclusion, our data demonstrate that CN and its bioactive compounds have inhibitory effects on premalignant prostate lesions induced by MNU + T and, therefore, may be considered for the chemoprevention of prostate cancer. PREVENTION RELEVANCE: The research work presented in this article demonstrates the chemopreventive efficacy of CN and its bioactive compounds in a rat model of premalignant prostate cancer.


Sujet(s)
Anticarcinogènes , États précancéreux , Tumeurs de la prostate , Humains , Rats , Mâle , Animaux , Prostate/anatomopathologie , Cinnamomum zeylanicum , Rat Wistar , Tumeurs de la prostate/induit chimiquement , Tumeurs de la prostate/prévention et contrôle , Tumeurs de la prostate/anatomopathologie , Anticarcinogènes/pharmacologie , Androgènes , États précancéreux/anatomopathologie , Carcinogenèse/anatomopathologie , Protéines membranaires/effets indésirables , Protéines membranaires/métabolisme , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/effets indésirables , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme
9.
Front Endocrinol (Lausanne) ; 13: 1027164, 2022.
Article de Anglais | MEDLINE | ID: mdl-36465608

RÉSUMÉ

Decidualization is the hormone-dependent process of endometrial remodeling that is essential for fertility and reproductive health. It is characterized by dynamic changes in the endometrial stromal compartment including differentiation of fibroblasts, immune cell trafficking and vascular remodeling. Deficits in decidualization are implicated in disorders of pregnancy such as implantation failure, intra-uterine growth restriction, and pre-eclampsia. Androgens are key regulators of decidualization that promote optimal differentiation of stromal fibroblasts and activation of downstream signaling pathways required for endometrial remodeling. We have shown that androgen biosynthesis, via 5α-reductase-dependent production of dihydrotestosterone, is required for optimal decidualization of human stromal fibroblasts in vitro, but whether this is required for decidualization in vivo has not been tested. In the current study we used steroid 5α-reductase type 1 (SRD5A1) deficient mice (Srd5a1-/- mice) and a validated model of induced decidualization to investigate the role of SRD5A1 and intracrine androgen signaling in endometrial decidualization. We measured decidualization response (weight/proportion), transcriptomic changes, and morphological and functional parameters of vascular development. These investigations revealed a striking effect of 5α-reductase deficiency on the decidualization response. Furthermore, vessel permeability and transcriptional regulation of angiogenesis signaling pathways, particularly those that involved vascular endothelial growth factor (VEGF), were disrupted in the absence of 5α-reductase. In Srd5a1-/- mice, injection of dihydrotestosterone co-incident with decidualization restored decidualization responses, vessel permeability, and expression of angiogenesis genes to wild type levels. Androgen availability declines with age which may contribute to age-related risk of pregnancy disorders. These findings show that intracrine androgen signaling is required for optimal decidualization in vivo and confirm a major role for androgens in the development of the vasculature during decidualization through regulation of the VEGF pathway. These findings highlight new opportunities for improving age-related deficits in fertility and pregnancy health by targeting androgen-dependent signaling in the endometrium.


Sujet(s)
3-Oxo-5-alpha-Steroid 4-Dehydrogenase , Caduques , Remodelage vasculaire , Animaux , Femelle , Souris , Grossesse , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/génétique , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , Androgènes/pharmacologie , Cholestenone 5 alpha-reductase/génétique , Cholestenone 5 alpha-reductase/métabolisme , Caduques/effets des médicaments et des substances chimiques , Caduques/métabolisme , 5alpha-Dihydrotestostérone/pharmacologie , Endomètre/effets des médicaments et des substances chimiques , Endomètre/métabolisme , Facteur de croissance endothéliale vasculaire de type A/génétique , Facteur de croissance endothéliale vasculaire de type A/métabolisme , Remodelage vasculaire/effets des médicaments et des substances chimiques , Remodelage vasculaire/génétique , Remodelage vasculaire/physiologie
10.
Nat Med ; 28(11): 2321-2332, 2022 11.
Article de Anglais | MEDLINE | ID: mdl-36357675

RÉSUMÉ

Garrod's concept of 'chemical individuality' has contributed to comprehension of the molecular origins of human diseases. Untargeted high-throughput metabolomic technologies provide an in-depth snapshot of human metabolism at scale. We studied the genetic architecture of the human plasma metabolome using 913 metabolites assayed in 19,994 individuals and identified 2,599 variant-metabolite associations (P < 1.25 × 10-11) within 330 genomic regions, with rare variants (minor allele frequency ≤ 1%) explaining 9.4% of associations. Jointly modeling metabolites in each region, we identified 423 regional, co-regulated, variant-metabolite clusters called genetically influenced metabotypes. We assigned causal genes for 62.4% of these genetically influenced metabotypes, providing new insights into fundamental metabolite physiology and clinical relevance, including metabolite-guided discovery of potential adverse drug effects (DPYD and SRD5A2). We show strong enrichment of inborn errors of metabolism-causing genes, with examples of metabolite associations and clinical phenotypes of non-pathogenic variant carriers matching characteristics of the inborn errors of metabolism. Systematic, phenotypic follow-up of metabolite-specific genetic scores revealed multiple potential etiological relationships.


Sujet(s)
Erreurs innées du métabolisme , Métabolome , Humains , Métabolome/génétique , Métabolomique , Plasma sanguin/métabolisme , Phénotype , Erreurs innées du métabolisme/génétique , Protéines membranaires/métabolisme , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/génétique , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme
11.
Phytomedicine ; 102: 154169, 2022 Jul 20.
Article de Anglais | MEDLINE | ID: mdl-35636178

RÉSUMÉ

BACKGROUND: Benign prostatic hyperplasia (BPH) is a urinary system disease with high prevalence among the middle and elder men. In BPH, proliferation of prostate cells and the imbanlance between androgen and estrogen are both important inducers. Previous studies have demonstrated that compounds from Ligustri Lucidi Fructus (LLF) and Ecliptae Herba (EH) are of phytoestrogenic or phytoandrogenic activities. The combination of LLF with EH at the ratio of 1:1 on crude drugs quantity is called Erzhi formula (EZF), which is used for in vivo research of our study. PURPOSE: This study aimed to investigate potential mechanisms of EZF and its active pharmaceutical ingredients on BPH in vitro and in vivo. METHODS: Therapeutic effects of EZF was evaluated in E2/testosterone (1:100) induced BPH rats model. The pathological changes of prostate, concentrations of testosterone, DHT, E2, PSA in rats' plasma and prostate were detected. The expressions of PCNA, AR, ERα, ERß, SRD5A1, SRD5A2 were measured in BPH rat prostates and E2-stimulated human benign prostatic epithelial cells (BPH-1). RESULTS: EZF treatment significantly attenuated rat prostate enlargement, alleviated BPH pathological features, and decreased the expression of PCNA. The up-regulation of AR, ERα, SRD5A1/2 expressions, and down-regulation of ERß expression at prostate of rat BPH model were significantly blocked by EZF administration. The expression levels of testosterone, DHT, E2, PSA were strongly inhibited by EZF treatment. At the cellular level, ligustrosidic acid and echinocystic acid inhibited E2-induced BPH-1 cell proliferation and PCNA expressions, which were consistent with the results in vivo. And these two ingredients also down-regulated the expressions of AR, ERα, SRD5A1/2 and up-regulated the expression of ERß in BPH-1 cells. CONCLUSION: EZF, ligustrosidic acid from LLF and echinocystic acid from EH showed inhibitive effects on BPH via down-regulating prostatic AR, ERα, SRD5A1/2 expressions and up-regulating ERß expression.


Sujet(s)
3-Oxo-5-alpha-Steroid 4-Dehydrogenase , Androgènes , Médicaments issus de plantes chinoises , Eclipta , Ligustrum , Phyto-oestrogènes , Hyperplasie de la prostate , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , Sujet âgé , Androgènes/pharmacologie , Animaux , Médicaments issus de plantes chinoises/pharmacologie , Eclipta/composition chimique , Oestradiol/métabolisme , Humains , Ligustrum/composition chimique , Mâle , Protéines membranaires/métabolisme , Phyto-oestrogènes/pharmacologie , Hyperplasie de la prostate/induit chimiquement , Hyperplasie de la prostate/traitement médicamenteux , Hyperplasie de la prostate/métabolisme , Rats , Testostérone/métabolisme
12.
Molecules ; 27(5)2022 Feb 24.
Article de Anglais | MEDLINE | ID: mdl-35268636

RÉSUMÉ

Oily skin from overactive sebaceous glands affects self-confidence and personality. There is report of an association between steroid 5-alpha reductase gene (SRD5A) expression and facial sebum production. There is no study of the effect of Asparagus racemosus Willd. root extract on the regulation of SRD5A mRNA expression and anti-sebum efficacy. This study extracted A. racemosus using the supercritical carbon dioxide fluid technique with ethanol and investigated its biological compounds and activities. The A. racemosus root extract had a high content of polyphenolic compounds, including quercetin, naringenin, and p-coumaric acid, and DPPH scavenging activity comparable to that of the standard L-ascorbic acid. A. racemosus root extract showed not only a significant reduction in SRD5A1 and SRD5A2 mRNA expression by about 45.45% and 90.86%, respectively, but also a reduction in the in vivo anti-sebum efficacy in male volunteers, with significantly superior percentage changes in facial sebum production and a reduction in the percentages of pore area after 15 and 30 days of treatment. It can be concluded that A. racemosus root extract with a high content of polyphenol compounds, great antioxidant effects, promising downregulation of SRD5A1 and SRD5A2, and predominant facial sebum reduction and pore-minimizing efficacy could be a candidate for an anti-sebum and pore-minimizing active ingredient to serve in functional cosmetic applications.


Sujet(s)
Asparagus , Dioxyde de carbone , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/génétique , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , Asparagus/composition chimique , Dioxyde de carbone/métabolisme , Humains , Mâle , Protéines membranaires/métabolisme , Extraits de plantes/métabolisme , Extraits de plantes/pharmacologie , ARN messager/génétique , ARN messager/métabolisme , Sébum
13.
Commun Biol ; 5(1): 233, 2022 03 15.
Article de Anglais | MEDLINE | ID: mdl-35293897

RÉSUMÉ

Prostate cancer (PCa) is the most frequent malignancy in male urogenital system around worldwide. We performed molecular subtyping and prognostic assessment based on consensus genes in patients with PCa. Five cohorts containing 1,046 PCa patients with RNA expression profiles and recorded clinical follow-up information were included. Univariate, multivariate Cox regression analysis and least absolute shrinkage and selection operator (LASSO) Cox regression were used to select prognostic genes and establish the signature. Immunohistochemistry staining, cell proliferation, migration and invasion assays were used to assess the biological functions of key genes. Thirty-nine intersecting consensus prognostic genes from five independent cohorts were identified. Subsequently, an eleven-consensus-gene classifier was established. In addition, multivariate Cox regression analyses showed that the classifier served as an independent indicator of recurrence-free survival in three of the five cohorts. Combined receiver operating characteristic (ROC) analysis achieved synthesized effects by combining the classifier with clinicopathological features in four of five cohorts. SRD5A2 inhibits cell proliferation, while ITGA11 promotes cell migration and invasion, possibly through the PI3K/AKT signaling pathway. To conclude, we established and validated an eleven-consensus-gene classifier, which may add prognostic value to the currently available staging system.


Sujet(s)
Phosphatidylinositol 3-kinases , Tumeurs de la prostate , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , Consensus , Analyse de profil d'expression de gènes , Régulation de l'expression des gènes tumoraux , Humains , Estimation de Kaplan-Meier , Mâle , Protéines membranaires/métabolisme , Phosphatidylinositol 3-kinases/métabolisme , Pronostic , Tumeurs de la prostate/diagnostic , Tumeurs de la prostate/génétique , Tumeurs de la prostate/métabolisme
14.
Aging (Albany NY) ; 14(4): 1743-1766, 2022 02 23.
Article de Anglais | MEDLINE | ID: mdl-35196258

RÉSUMÉ

Hepatocellular carcinoma (HCC) is the most common malignant liver tumor with high mortality and poor prognosis worldwide. This study aimed to identify hub genes and investigate the underlying molecular mechanisms in HCC progression by integrated bioinformatics analysis and experimental validation. Based on the Gene Expression Omnibus (GEO) databases and The Cancer Genome Atlas (TCGA), 12 critical differential co-expression genes were identified between tumor and normal tissues. Via survival analysis, we found higher expression of LCAT, ACSM3, IGF1, SRD5A2, THRSP and ACADS was associated with better prognoses in HCC patients. Among which, THRSP was selected for the next investigations. We found that THRSP mRNA expression was negatively correlated with its methylation and closely associated with clinical characteristics in HCC patients. Moreover, THRSP expression had a negative correlation with the infiltration levels of several immune cells (e.g., B cells and CD4+ T cells). qRT-PCR verified that THRSP was lower expressed in HCC tissues and cell lines compared with control. Silencing of THRSP promoted the migration, invasion, proliferation, and inhibited cell apoptosis of HCCLM and Huh7 cell lines. Decreased expression of THRSP promoted HCC progression by NF-κB, ERK1/2, and p38 MAPK signaling pathways. In conclusion, THRSP might serve as a novel biomarker and therapeutic target of HCC.


Sujet(s)
Carcinome hépatocellulaire , Tumeurs du foie , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , Marqueurs biologiques tumoraux/génétique , Marqueurs biologiques tumoraux/métabolisme , Carcinome hépatocellulaire/anatomopathologie , Biologie informatique , Régulation de l'expression des gènes tumoraux , Humains , Tumeurs du foie/anatomopathologie , Protéines membranaires/génétique , Pronostic
15.
BMC Biol ; 20(1): 11, 2022 01 07.
Article de Anglais | MEDLINE | ID: mdl-34996447

RÉSUMÉ

BACKGROUND: Women facing increased energetic demands in childhood commonly have altered adult ovarian activity and shorter reproductive lifespan, possibly comprising a strategy to optimize reproductive success. Here, we sought to understand the mechanisms of early-life programming of reproductive function, by integrating analysis of reproductive tissues in an appropriate mouse model with methylation analysis of proxy tissue DNA in a well-characterized population of Bangladeshi migrants in the UK. Bangladeshi women whose childhood was in Bangladesh were found to have later pubertal onset and lower age-matched ovarian reserve than Bangladeshi women who grew-up in England. Subsequently, we aimed to explore the potential relevance to the altered reproductive phenotype of one of the genes that emerged from the screens. RESULTS: Of the genes associated with differential methylation in the Bangladeshi women whose childhood was in Bangladesh as compared to Bangladeshi women who grew up in the UK, 13 correlated with altered expression of the orthologous gene in the mouse model ovaries. These mice had delayed pubertal onset and a smaller ovarian reserve compared to controls. The most relevant of these genes for reproductive function appeared to be SRD5A1, which encodes the steroidogenic enzyme 5α reductase-1. SRD5A1 was more methylated at the same transcriptional enhancer in mice ovaries as in the women's buccal DNA, and its expression was lower in the hypothalamus of the mice as well, suggesting a possible role in the central control of reproduction. The expression of Kiss1 and Gnrh was also lower in these mice compared to controls, and inhibition of 5α reductase-1 reduced Kiss1 and Gnrh mRNA levels and blocked GnRH release in GnRH neuronal cell cultures. Crucially, we show that inhibition of this enzyme in female mice in vivo delayed pubertal onset. CONCLUSIONS: SRD5A1/5α reductase-1 responds epigenetically to the environment and its downregulation appears to alter the reproductive phenotype. These findings help to explain diversity in reproductive characteristics and how they are shaped by early-life environment and reveal novel pathways that might be targeted to mitigate health issues caused by life-history trade-offs.


Sujet(s)
3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , Cholestenone 5 alpha-reductase , Kisspeptines , Protéines membranaires/métabolisme , Adaptation physiologique , Animaux , Cholestenone 5 alpha-reductase/génétique , Cholestenone 5 alpha-reductase/métabolisme , Épigenèse génétique , Femelle , Hormone de libération des gonadotrophines/génétique , Hormone de libération des gonadotrophines/métabolisme , Humains , Kisspeptines/génétique , Kisspeptines/métabolisme , Souris
16.
Front Endocrinol (Lausanne) ; 12: 759971, 2021.
Article de Anglais | MEDLINE | ID: mdl-34764940

RÉSUMÉ

Alterations in glucocorticoid metabolism may contribute to the development of obesity and insulin resistance (IR). Obesity in turn affects the androgen balance. The peripheral metabolism of steroids is equally an important determinant of their bioavailability and activity. The aim of this study was to evaluate steroid metabolism in obese children and to define which enzyme alterations are associated with IR. Clinical characteristics and anthropometric measurements were determined in 122 obese children and adolescents (72 girls, 50 boys) aged 8 - 18 years. 26 of them (21.3%) were diagnosed with IR (13 boys, 13 girls). Routine laboratory tests were performed and 24h urinary steroid excretion profiles were analyzed by gas chromatography/mass spectrometry. Positive relationship between 5α-reductase (SRD5A) activity and IR was found. According to the androsterone to etiocholanolone (An/Et) ratio the activity of SRD5A was significantly increased in obese children with IR, but the difference remained insignificant once the 5α-dihydrotestosterone to testosterone (5αDHT/T) ratio was considered. Furthermore, this relationship persisted in boys but was not observed in girls. The activity of 20α-hydroxysteroid dehydrogenase (20αHSD) and 20ß-hydroxysteroid dehydrogenase (20ßHSD) was reduced only in obese girls with IR. Conclude, in the context of obese children and adolescents with IR, we surmise that increased SRD5A represents a compensatory mechanism to reduce local glucocorticoid availability. This phenomenon is probably different in the liver (restriction) and in the adipose tissue (expected increase in activity). We show significant changes in 20αHSD and 20ßHSD activity in obese girls with IR, but it is difficult to clearly determine whether the activity of these enzymes is an indicator of the function in their ovaries or adrenal glands.


Sujet(s)
20-alpha-Hydroxysteroid dehydrogenase/métabolisme , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , Cortisone reductase/métabolisme , Insulinorésistance , Protéines membranaires/métabolisme , Obésité pédiatrique/enzymologie , Adolescent , Études cas-témoins , Enfant , Femelle , Humains , Mâle , Stéroïdes/urine
17.
Biomolecules ; 11(4)2021 04 08.
Article de Anglais | MEDLINE | ID: mdl-33917905

RÉSUMÉ

Network-based methods for the analysis of drug-target interactions have gained attention and rely on the paradigm that a single drug can act on multiple targets rather than a single target. In this study, we have presented a novel approach to analyze the interactions between the chemicals in the medicinal plants and multiple targets based on the complex multipartite network of the medicinal plants, multi-chemicals, and multiple targets. The multipartite network was constructed via the conjunction of two relationships: chemicals in plants and the biological actions of those chemicals on the targets. In doing so, we introduced an index of the efficacy of chemicals in a plant on a protein target of interest, called target potency score (TPS). We showed that the analysis can identify specific chemical profiles from each group of plants, which can then be employed for discovering new alternative therapeutic agents. Furthermore, specific clusters of plants and chemicals acting on specific targets were retrieved using TPS that suggested potential drug candidates with high probability of clinical success. We expect that this approach may open a way to predict the biological functions of multi-chemicals and multi-plants on the targets of interest and enable repositioning of the plants and chemicals.


Sujet(s)
, Plantes médicinales/composition chimique , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/composition chimique , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , Algorithmes , Analyse de regroupements , Bases de données chimiques , Préparations pharmaceutiques/composition chimique , Préparations pharmaceutiques/métabolisme , Plantes médicinales/métabolisme , Récepteurs aux androgènes/composition chimique , Récepteurs aux androgènes/métabolisme
18.
Front Endocrinol (Lausanne) ; 12: 657360, 2021.
Article de Anglais | MEDLINE | ID: mdl-33833737

RÉSUMÉ

Although 11-ketotestosterone (11KT) and testosterone (T) are major androgens in both teleosts and humans, their 5α-reduced derivatives produced by steroid 5α-reductase (SRD5A/srd5a), i.e., 11-ketodihydrotestosterone (11KDHT) and 5α-dihydrotestosterone (DHT), remains poorly characterized, especially in teleosts. In this study, we compared the presence and production of DHT and 11KDHT in Japanese eels and humans. Plasma 11KT concentrations were similar in both male and female eels, whereas T levels were much higher in females. In accordance with the levels of their precursors, 11KDHT levels did not show sexual dimorphism, whereas DHT levels were much higher in females. It is noteworthy that plasma DHT levels in female eels were higher than those in men. In addition, plasma 11KDHT was undetectable in both sexes in humans, despite the presence of 11KT. Three srd5a genes (srd5a1, srd5a2a and srd5a2b) were cloned from eel gonads. All three srd5a genes were expressed in the ovary, whereas only both srd5a2 genes were expressed in the testis. Human SRD5A1 was expressed in testis, ovary and adrenal, whereas SRD5A2 was expressed only in testis. Human SRD5A1, SRD5A2 and both eel srd5a2 isoforms catalyzed the conversion of T and 11KT into DHT and 11KDHT, respectively, whereas only eel srd5a1 converted T into DHT. DHT and 11KDHT activated eel androgen receptor (ar)α-mediated transactivation as similar fashion to T and 11KT. In contrast, human AR and eel arß were activated by DHT and11KDHT more strongly than T and 11KT. These results indicate that in teleosts, DHT and 11KDHT may be important 5α-reduced androgens produced in the gonads. In contrast, DHT is the only major 5α-reduced androgens in healthy humans.


Sujet(s)
3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , Androgènes/sang , 5alpha-Dihydrotestostérone/sang , Gonades/métabolisme , Protéines membranaires/métabolisme , Récepteurs aux androgènes/métabolisme , Testostérone/analogues et dérivés , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/génétique , Animaux , Anguilliformes , Femelle , Humains , Mâle , Protéines membranaires/génétique , Récepteurs aux androgènes/génétique , Testostérone/sang
19.
Molecules ; 26(4)2021 Feb 08.
Article de Anglais | MEDLINE | ID: mdl-33567691

RÉSUMÉ

Steroid 5-α reductase (5AR) is responsible for the reduction of steroids to 5-α reduced metabolites, such as the reduction of testosterone to 5-α dihydrotestosterone (DHT). A new adverse outcome pathway (AOP) for 5AR inhibition to reduce female reproduction in fish (AOP 289) is under development to clarify the antiestrogenic effects of 5AR inhibitors in female fish. A sensitive method for the DHT analysis using chemical derivatization and liquid chromatography-tandem mass spectrometry was developed. A cell-based 5AR inhibition assay that utilizes human cell lines, a transient overexpression system, and fish cell lines was developed. The measured IC50 values of two well-known 5AR inhibitors, finasteride and dutasteride, were comparable in the different systems. However, the IC50 of dutasteride in the fish cell lines was lower than that in the human cell lines. Finasteride showed a higher IC50 against the RTG-2 cell line. These results demonstrated that 5ARs inhibition could differ in terms of structural characteristics among species. The assay has high sensitivity and reproducibility and is suitable for the application in 5AR inhibition screening for various endocrine disruption chemicals (EDCs). Future studies will continue to evaluate the quantitative inhibition of 5AR by EDCs to compare the endocrine-disrupting pathway in different species.


Sujet(s)
3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , Inhibiteurs de la 5-alpha réductase/pharmacologie , Chromatographie en phase liquide , Évaluation préclinique de médicament/méthodes , Spectrométrie de masse , Animaux , Calibrage , Lignée cellulaire , Humains , Oncorhynchus mykiss , Danio zébré
20.
Cell Death Dis ; 12(2): 206, 2021 02 24.
Article de Anglais | MEDLINE | ID: mdl-33627630

RÉSUMÉ

Steroid 5α-reductase type I (SRD5A1) is a validated oncogene in many sex hormone-related cancers, but its role in multiple myeloma (MM) remains unknown. Based on gene expression profiling (GEP) of sequential MM samples during the disease course, we found that the aberrant expression of SRD5A1 was correlated with progression and poor prognosis in MM patients. In this study, the oncogenic roles of SRD5A1 were validated in human MM cell lines (ARP1 and H929) and the xenograft MM model as well as the 5TMM mouse model. MTT and flow cytometry were used to assess MM cell proliferation, cell cycle, and apoptosis post inducible knockdown SRD5A1 by lentivirus-mediated short-hairpin RNA (shRNA). Transcriptomic sequencing, immunofluorescence, and western blot were used to investigate the effects of SRD5A1 suppression on cell apoptosis and autophagy. Mechanistically, SRD5A1 downregulation simultaneously regulated both the Bcl-2 family protein-mediated apoptosis and the autophagic process via PI3K/Akt/mTOR signaling pathway in MM cells. Meanwhile, the autophagy inhibitor (3-methyladenine) and SRD5A1 inhibitor (Dutasteride) were utilized to evaluate their anti-myeloma effect. Thus, our results demonstrated that SRD5A1 downregulation simultaneously regulated both the apoptosis and the autophagic process in MM cells. The dual autophagy-apoptosis regulatory SRD5A1 may serve as a biomarker and potential target for MM progression and prognosis.


Sujet(s)
3-Oxo-5-alpha-Steroid 4-Dehydrogenase/métabolisme , Apoptose , Autophagie , Protéines membranaires/métabolisme , Myélome multiple/enzymologie , Phosphatidylinositol 3-kinase/métabolisme , Protéines proto-oncogènes c-akt/métabolisme , Sérine-thréonine kinases TOR/métabolisme , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/génétique , Inhibiteurs de la 5-alpha réductase/pharmacologie , Adénine/analogues et dérivés , Adénine/pharmacologie , Animaux , Antinéoplasiques/pharmacologie , Apoptose/effets des médicaments et des substances chimiques , Autophagie/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Prolifération cellulaire , Dutastéride/pharmacologie , Répression enzymatique , Femelle , Régulation de l'expression des gènes tumoraux , Humains , Mâle , Protéines membranaires/antagonistes et inhibiteurs , Protéines membranaires/génétique , Souris de lignée C57BL , Souris de lignée NOD , Myélome multiple/traitement médicamenteux , Myélome multiple/génétique , Myélome multiple/anatomopathologie , Transduction du signal
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...